SITC Cancer Immunotherapy Guideline – Multiple Myeloma

SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of clinical 
practice guidelines developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced and will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

The SITC consensus statement on immunotherapy for the treatment of multiple myeloma was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. Containing consensus recommendations regarding FDA-approved immunotherapies for multiple myeloma, as well as discussion of promising emerging treatment modalities including chimeric antigen receptor T cell therapies and novel monoclonal antibody agents directed against B cell maturation antigen, this clinical practice guideline will provide a valuable resource for the multiple myeloma community.

SITC Multiple Myeloma Immunotherapy Guideline Expert Panel

Members

Jack Aiello, MS — Patient Advocate

David E. Avigan, MD — Beth Israel Deaconess Medical Center

Jesus G. Berdeja, MD —  Sarah Cannon Research Institute

Ivan M. Borrello, MD — The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Ajai Chari, MD —  Icahn School of Medicine at Mount Sinai

Adam D. Cohen, MD — Abramson Cancer Center at the University of Pennsylvania

Karthik Ganapathi, MD — University of California San Francisco

Lissa Gray, FNP, MSN — University of California San Francisco

Damian Green, MD — Fred Hutchinson Cancer Research Center

Amrita Krishnan, MD — Judy and Bernard Briskin Multiple Myeloma Center for Clinical Research, City of Hope Comprehensive Cancer Center

Yi Lin, MD, PhD — Mayo Clinic

Elisabet Manasanch, MD, M.H.Sc. — The University of Texas MD Anderson Cancer Center

Nikhil C. Munshi, MD — Dana-Farber Cancer Institute

Ajay K. Nooka, MD, MPH, FACP — Emory University

Aaron P. Rapoport, MD — University of Maryland Greenebaum Comprehensive Cancer Center

Eric L. Smith, MD, PhD — Memorial Sloan Kettering Cancer Center

Ravi Vij, MBBS, MD — Washington University School of Medicine in St. Louis